Trial Profile
A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Subjects With Severely Impaired Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Feb 2022
Price :
$35
*
At a glance
- Drugs Azelaprag (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors Amgen
- 29 Jan 2022 Results published in the Drugs in R and D
- 29 Jan 2021 Study design changed from sequential to parallel
- 04 May 2018 Status changed from active, no longer recruiting to completed.